Sage Journals: Discover world-class research

Abstract

Introduction: Hyperparathyroidism, characterized by elevated parathyroid hormone (PTH) levels, predominantly affects women aged 50 to 60 years. Traditional treatments, such as parathyroidectomy and calcimimetics, pose risks including hypocalcemia and gastrointestinal issues. This study evaluates a novel treatment using plant-derived oils, comparing its efficacy to conventional therapies. Materials and Methods: Over 5 years, 3,230 subjects were examined using BDORT. Among them, 51 were diagnosed with hyperparathyroidism, with 30 exhibiting elevated PTH levels. Fourteen patients (12 females, 2 males) were treated with Parathyroid Recovery, an oil mixture formulated via BDORT. PTH levels were measured pre- and post-treatment. Molecular docking studies assessed the binding affinities of traditional drugs (Cinacalcet, Teriparatide) and natural compounds (Capsorubin, Quercetin-3-Rutinoside) from the oil blend to the calcium-sensing receptor (CaSR). Results: The plant oil mixture significantly reduced PTH levels, with an average decrease of 18.97 pg/mL (ρ < 0.002, ***). Molecular docking revealed that Capsorubin and Quercetin-3-Rutinoside exhibited stronger binding affinities to CaSR (−6.9 kcal/mol) than conventional drugs. A strong negative correlation (≈ −0.77) was observed between Vitamin D levels and pre-treatment PTH levels, emphasizing Vitamin D's role in hyperparathyroidism management. Discussion and Conclusions: The superior CaSR binding affinities of Capsorubin and Quercetin-3-Rutinoside correlate with clinical PTH reductions, suggesting enhanced therapeutic efficacy. Older patients exhibited greater responsiveness. BDORT proves valuable for both diagnosis and treatment formulation. These findings support plant-derived oils as a promising alternative to conventional therapies. Future research should validate these results through larger clinical trials and mechanistic studies, optimizing treatment protocols.

Keywords

hyperparathyroidism parathyroid hormone calcimimetics plant-derived oils chronic kidney disease PTH immunoassay novel therapeutics molecular docking bi-digital O-ring test (BDORT)

Get full access to this article

View all access options for this article.

References

Ahmadieh

Kreidieh

Akl

E. A.

El-Hajj Fuleihan

(2020). Minimally invasive parathyroidectomy guided by intraoperative parathyroid hormone monitoring (IOPTH) and preoperative imaging versus bilateral neck exploration for primary hyperparathyroidism in adults. Cochrane Database of Systematic Reviews, 10(10), CD010787. https://doi.org/10.1002/14651858.CD010787.pub2

Allerheiligen

D. A.

Schoeber

Houston

R. E.

Mohl

V. K.

Wildman

K. M.

(1998). Hyperparathyroidism. American Family Physician, 57(8), 1795–1802, 1807–1808.

Amgen Inc. (2014). Sensipar: Highlights of prescribing information (PDF). https://web.archive.org/web/20141005000000/https://www.amgen.com.

Andrassy

K. M.

(2013). Comments on ‘KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease’. Kidney International, 84(3), 622–623. https://doi.org/10.1038/ki.2013.243

Arnaud

C. D.

Tenenhouse

A. M.

Rasmussen

(1967). Parathyroid hormone. Annual Review of Physiology, 29(1), 349–372. https://doi.org/10.1146/annurev.ph.29.030167.002025

Ballinger

A. E.

Palmer

S. C.

Nistor

Craig

J. C.

Strippoli

G. F.

(2014). Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients. Cochrane Database of Systematic Reviews, 2014(12), CD006254. https://doi.org/10.1002/14651858.CD006254.pub2

Baran

Turkmani

M. G.

Mubki

(2014). Acquired racquet nails: A useful sign of hyperparathyroidism. Journal of the European Academy of Dermatology and Venereology, 28(2), 257–259. https://doi.org/10.1111/jdv.12187

Bilezikian

J. P.

Silverberg

S. J.

(2004). Clinical practice: Asymptomatic primary hyperparathyroidism. New England Journal of Medicine, 350(17), 1746–1751. https://doi.org/10.1056/NEJMcp032200

Blaine

Chonchol

Levi

(2015). Renal control of calcium, phosphate, and magnesium homeostasis. Clinical Journal of the American Society of Nephrology, 10(7), 1257–1272. https://doi.org/10.2215/CJN.09750913

10.

Brown

E. M.

(2009). Anti-parathyroid and anti-calcium sensing receptor antibodies in autoimmune hypoparathyroidism. Endocrinology and Metabolism Clinics of North America, 38(2), 437–445. https://doi.org/10.1016/j.ecl.2009.01.001

11.

Brown

E. M.

MacLeod

R. J.

(2001). Extracellular calcium sensing and extracellular calcium signaling. Physiological Reviews, 81(1), 239–297. https://doi.org/10.1152/physrev.2001.81.1.239

12.

Cai

Shao

Maigret

(2002). Protein–ligand recognition using spherical harmonic molecular surfaces: Towards a fast and efficient filter for large virtual throughput screening. Journal of Molecular Graphics and Modelling, 20(4), 313–328. https://doi.org/10.1016/S1093-3263(01)00134-6

13.

Carroll

M. F.

Schade

D. S.

(2003). A practical approach to hypercalcemia. American Family Physician, 67(9), 1959–1966.

14.

Compher

C. W.

Badellino

K. O.

Boullata

J. I.

(2008). Vitamin D and the bariatric surgical patient: A review. Obesity Surgery, 18(2), 220–224. https://doi.org/10.1007/s11695-007-9289-6

15.

du Preez

Adams

Richards

Whitley

(2016). Hyperparathyroidism jaw tumour syndrome: A pictoral review. Insights Into Imaging, 7(6), 793–800. https://doi.org/10.1007/s13244-016-0519-0

16.

Dulfer

R. R.

Franssen

G. J.

Hesselink

D. A.

Hoorn

E. J.

van Eijck

C. H.

van Ginhoven

T. M.

(2017). Systematic review of surgical and medical treatment for tertiary hyperparathyroidism. British Journal of Surgery, 104(7), 804–813. https://doi.org/10.1002/bjs.10554

17.

Dunjic

Turini

S. G.

Stanisic

Sulovic

Cvetkovic

Mihajlovic

Dunjic

Simic

Dunjic

(2021). New approach to create an effective natural treatments of infections caused by human papillomavirus. Journal of Molecular Docking, 1(2), 68–77. https://doi.org/10.33084/jmd.v1i2.3011

18.

Eckardt

K. U.

Kasiske

B. L.

(2009). KDIGO Clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney International, 76(113), S1–S2. https://doi.org/10.1038/ki.2009.188

19.

Feig

Onufriev

Lee

M. S.

Case

D. A.

Brooks

C. L.

(2004). Performance comparison of generalized born and Poisson methods in the calculation of electrostatic solvation energies for protein structures. Journal of Computational Chemistry, 25(2), 265–284. https://doi.org/10.1002/jcc.10378

20.

Fraser

W. D.

(2009). Hyperparathyroidism. The Lancet, 374(9684), 145–158. https://doi.org/10.1016/S0140-6736(09)60507-9

21.

Gasparri

Camandona

Palestini

(2015). Primary, secondary and tertiary hyperparathyroidism: Diagnostic and therapeutic updates. Springer.

22.

Giovanella

Bacigalupo

Treglia

Piccardo

(2021). Will 18F-fluorocholine PET/CT replace other methods of preoperative parathyroid imaging? Endocrine, 71(2), 285–297. https://doi.org/10.1007/s12020-020-02487-y

23.

Griebeler

M. L.

Kearns

A. E.

Ryu

Thapa

Hathcock

M. A.

Melton

L. J.

Wermers

R. A.

(2016). Thiazide-associated hypercalcemia: Incidence and association with primary hyperparathyroidism over two decades. The Journal of Clinical Endocrinology & Metabolism, 101(3), 1166–1173. https://doi.org/10.1210/jc.2015-3964

24.

Hannan

F. M.

Kallay

Chang

Brandi

M. L.

Thakker

R. V.

(2019). The calcium-sensing receptor in physiology and in calcitropic and noncalcitropic diseases. Nature Reviews Endocrinology, 15(1), 33–51. https://doi.org/10.1038/s41574-018-0115-0

25.

Harrison

T. R.

Adams

R. D.

Bennett

I. L.

Resnick

W. H.

Thorn

G. W.

Wintrobe

M. M.

(1958). Metabolic and endocrine disorders. In Principles of internal medicine (3rd ed., pp. 575–578). McGraw-Hill Book Company.

26.

Saunders

Safley

Smith

M. R.

Liang

Tran

, et al. (2021). Environmental chemicals and metabolic disruption in primary and secondary human parathyroid tumors. Surgery, 169(1), 102–108. https://doi.org/10.1016/j.surg.2020.06.010

27.

Hyperparathyroidism. (2021). The Lecturio Medical Concept Library. https://www.lecturio.com.

28.

Ketteler

Block

G. A.

Evenepoel

Fukagawa

Herzog

C. A.

McCann

Moe

S. M.

Shroff

Tonelli

M. A.

Toussaint

N. D.

Vervloet

M. G.

Leonard

M. B.

(2017). Executive summary of the 2017 KDIGO chronic kidney disease–mineral and bone disorder (CKD-MBD) guideline update: What’s changed and why it matters. Kidney International, 92(1), 26–36. https://doi.org/10.1016/j.kint.2017.04.006

29.

Klein

G. L.

Castro

S. M.

Garofalo

R. P.

(2016). The calcium-sensing receptor as a mediator of inflammation. Seminars in Cell & Developmental Biology, 49, 52–56. https://doi.org/10.1016/j.semcdb.2015.08.006

30.

Kumar

Thompson

J. R.

(2011). The regulation of parathyroid hormone secretion and synthesis. Journal of the American Society of Nephrology, 22(2), 216–224. https://doi.org/10.1681/ASN.2010020186

31.

Kyriazidis

Kamani

Randolph

(2016). Anatomy and embryology of the parathyroid gland. Operative Techniques in Otolaryngology-Head and Neck Surgery, 27(3), 117–121. https://doi.org/10.1016/j.otot.2016.06.003

32.

Bhushan

Sochat

Kallianos

Chavda

Zureick

A. H.

Kalani

(2017). First aid for the USMLE step 1 2017. McGraw-Hill Education.

33.

Lee

J. Y.

Shoback

D. M.

(2018). Familial hypocalciuric hypercalcemia and related disorders. Best Practice & Research Clinical Endocrinology & Metabolism, 32(5), 609–619. https://doi.org/10.1016/j.beem.2018.05.004

34.

Lips

(2001). Vitamin D deficiency and secondary hyperparathyroidism in the elderly: Consequences for bone loss and fractures and therapeutic implications. Endocrine Reviews, 22(4), 477–501. https://doi.org/10.1210/edrv.22.4.0437

35.

Marx

S. J.

(2011). Hyperparathyroid genes: Sequences reveal answers and questions. Endocrine Practice, 17(Suppl 3), 18–27. https://doi.org/10.4158/EP11067.RA

36.

Massy

Z. A.

Hénaut

Larsson

T. E.

Vervloet

M. G.

(2014). Calcium-sensing receptor activation in chronic kidney disease: Effects beyond parathyroid hormone control. Seminars in Nephrology, 34(6), 648–659. https://doi.org/10.1016/j.semnephrol.2014.10.001

37.

McDow

A. D.

Sippel

R. S.

(2018). Should symptoms be considered an indication for parathyroidectomy in primary hyperparathyroidism? Clinical Medicine Insights: Endocrinology and Diabetes, 11, 1179551418785135. https://doi.org/10.1177/1179551418785135

38.

McKenna

Rahman

Parham

(2020). Otoconia degeneration as a consequence of primary hyperparathyroidism. Medical Hypotheses, 144, 109982. https://doi.org/10.1016/j.mehy.2020.109982

39.

Mcule. (n.d.). 1-Click Docking. Retrieved from https://mcule.com/apps/1-click-docking/.

40.

MDedge. (2023). Primary hyperparathyroidism: A case-based review | Clinician Reviews. MDedge.

41.

Michels

T. C.

Kelly

K. M.

(2013). Parathyroid disorders. American Family Physician, 88(4), 249–257.

42.

Minisola

Arnold

Belaya

Brandi

M. L.

Clarke

B. L.

Hannan

F. M.

Hofbauer

L. C.

Insogna

K. L.

Lacroix

Liberman

Palermo

Pepe

Rizzoli

Wermers

Thakker

R. V.

(2020). Epidemiology, pathophysiology, and genetics of primary hyperparathyroidism. Journal of Bone and Mineral Research, 37(11), 2315–2329. https://doi.org/10.1002/jbmr.4665

43.

Morris

R. J.

Najmanovich

R. J.

Kahraman

Thornton

J. M.

(2005). Real spherical harmonic expansion coefficients as 3D shape descriptors for protein binding pocket and ligand comparisons. Bioinformatics, 21(10), 2347–2355. https://doi.org/10.1093/bioinformatics/bti337

44.

National Endocrine and Metabolic Diseases Information Service. (2006). Hyperparathyroidism [Archived May 24, 2011, at the Wayback Machine]. https://www.niddk.nih.gov/health-information/endocrine-diseases/hyperparathyroidism.

45.

Neish

A. S.

Nagel

J. S.

Holman

B. L.

(2021). Parathyroid adenoma. BrighamRAD Teaching Case Database. [Archived from the original on July 16, 2011]. https://web.archive.org/web/20110716000000/http://brighamrad.harvard.edu/.

46.

Omura

Chen

Lermand

Jones

Duvvi

Shimotsuura

(2010). Effects of transcutaneous electrical stimulation (1 pulse/sec) through custom-made disposable surface electrodes covering omura’s ST36 area of both legs on normal cell telomeres, oncogen C-fosAb2, integrin α₅β₁, Chlamydia trachomatis, etc. In breast cancer & Alzheimer patients. Acupuncture & Electro-Therapeutics Research, 35(3-4), 147–185. https://doi.org/10.3727/036012910803860922

47.

Omura

Chen

D. P.

Shimotsura

Ohki

Duvvi

(2007). Anatomical relationship between traditional acupuncture point ST 36 and omura’s ST 36 (true ST 36) with their therapeutic effects: (1) inhibition of cancer cell division by markedly lowering cancer cell telomere while increasing normal cell telomere, (2) improving circulatory disturbances, with reduction of abnormal increase in high triglyceride, L-homocystein, CRP, or cardiac troponin I & T in blood by the stimulation of omura’s ST 36—part 1. Acupuncture & Electro-Therapeutics Research, 32(1-2), 31–70.

48.

Omura

O’Young

Jones

Pallos

Duvvi

Shimotsuura

(2011). Caprylic acid in the effective treatment of intractable medical problems of frequent urination, incontinence, chronic upper respiratory infection, root canalled tooth infection, ALS, etc., caused by asbestos & mixed infections of Candida albicans, Helicobacter pylori & cytomegalovirus with or without other microorganisms & mercury. Acupuncture & Electro-Therapeutics Research, 36(1-2), 19–64. https://doi.org/10.3727/036012911803860886

49.

Ott

S. M.

(1998). Calcimimetics—new drugs with the potential to control hyperparathyroidism. The Journal of Clinical Endocrinology & Metabolism, 83(4), 1080–1082. https://doi.org/10.1210/jcem.83.4.4799

50.

Palumbo

Damiano

Messina

(2021). Tertiary hyperparathyroidism: A review. La Clinica Terapeutica, 172(3), 241–246. https://doi.org/10.7417/CT.2021.2322

51.

Pomerantz

J. M.

(2010). Hyperparathyroidism resulting from lithium treatment remains underrecognized. Drug Benefit Trends, 22, 62–63. [Archived from the original on July 1, 2010]. https://doi.org/web/20100701000000/http://www.drugbenefittrends.com

52.

Randle

R. W.

Balentine

C. J.

Wendt

Schneider

D. F.

Chen

Sippel

R. S.

(2016). Should vitamin D deficiency be corrected before parathyroidectomy? Journal of Surgical Research, 204(1), 94–100. https://doi.org/10.1016/j.jss.2016.04.022

53.

Saliba

El-Haddad

(2009). Secondary hyperparathyroidism: Pathophysiology and treatment. The Journal of the American Board of Family Medicine, 22(5), 574–581. https://doi.org/10.3122/jabfm.2009.05.090026

54.

Shoichet

B. K.

Kuntz

I. D.

Bodian

D. L.

(1992). Molecular docking using shape descriptors. Journal of Computational Chemistry, 13(3), 380–397. https://doi.org/10.1002/jcc.540130311

55.

Silva

B. C.

Bilezikian

J. P.

(2015). Parathyroid hormone: Anabolic and catabolic actions on the skeleton. Current Opinion in Pharmacology, 22, 41–50. https://doi.org/10.1016/j.coph.2015.03.005

56.

Stryer

(1995). Biochemistry (4th ed). W.H. Freeman and Company.

57.

Sulaiman

Nilsson

I. L.

Juhlin

C. C.

Haglund

Höög

Larsson

Hashemi

(2012). Genetic characterization of large parathyroid adenomas. Endocrine-Related Cancer, 19(3), 389–407. https://doi.org/10.1530/ERC-11-0140

58.

Szalat

Mazeh

Freund

H. R.

(2009). Lithium-associated hyperparathyroidism: Report of four cases and review of the literature. European Journal of Endocrinology, 160(2), 317–323. https://doi.org/10.1530/EJE-08-0620

59.

Taniegra

E. D.

(2004). Hyperparathyroidism. American Family Physician, 69(2), 333–339.

60.

Thakker

R. V.

(2015). The calcium-sensing receptor: And its involvement in parathyroid pathology. Annales D’Endocrinologie, 76(2), 81–83. https://doi.org/10.1016/j.ando.2015.03.013

61.

van der Plas

W. Y.

Noltes

M. E.

van Ginhoven

T. M.

Kruijff

(2020). Secondary and tertiary hyperparathyroidism: A narrative review. Scandinavian Journal of Surgery, 109(4), 271–278. https://doi.org/10.1177/1457496919866015

62.

Varghese

Rich

Jimenez

(2011). Benign familial hypocalciuric hypercalcemia. Endocrine Practice, 17, 13–17. https://doi.org/10.4158/EP10308.RA

63.

Waghray

Milas

Nyalakonda

Siperstein

A. E.

(2013). Falsely low parathyroid hormone secondary to biotin interference: A case series. Endocrine Practice, 19(3), 451–455. https://doi.org/10.4158/EP12158.OR

64.

Yeh

M. W.

Ituarte

P. H.

Zhou

H. C.

Nishimoto

Liu

Harari

Haigh

P. I.

Adams

A. L.

(2013). Incidence and prevalence of primary hyperparathyroidism in a racially mixed population. The Journal of Clinical Endocrinology & Metabolism, 98(3), 1122–1129. https://doi.org/10.1210/jc.2012-4022

Bi-digital O-ring Test (BDORT),Coupled with Molecular Docking Analysis,for Improving Parathyroid Gland Health: Clinical Insights into Combined Oils Therapy for Treating Hyper-Parathyroidism

Abstract

Keywords

Get full access to this article

References